Quimioterapia neoadyuvante como tratamiento del carcinoma lobulillar mamario. ¿Ha llegado el momento del cambio?

Benefits of primary chemotherapy in cases of breast invasive ductal carcinoma are widely accepted. However, the use of this therapy is controversial in cases of lobular invasive carcinoma: response rates are very poor-but not prognosis- and cases in which the breast can be conserved are very few. We present a rare case of bilateral synchronous breast cancer, a ductal carcinoma in the right breast and a lobular carcinoma in the left breast. It illustrates very clearly the controversy in which we currently are.